熱門資訊> 正文
J&J/Contineum抑郁症候选人在第2阶段失败
2026-09-15 04:49
- An asset for major depressive disorder licensed to Johnson & Johnson (JNJ) from Contineum Therapeutics (CTNM) missed its primary endpoint in a phase 2 trial.
- In the MOONLIGHT-1 trial, JNJ-5120/PIPE-307 did not improve the Montgomery-Åsberg Depression Rating Scale (MADRS) total score compared with placebo.
- J&J will continue to evaluate the data to determine next steps.
- JNJ-5120, an M1 muscarinic receptor antagonist, also failed a phase 2 trial for relapsing-remitting multiple sclerosis in November 2025.
More on Johnson & Johnson
- Johnson & Johnson (JNJ) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- Johnson & Johnson (JNJ) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
- Johnson & Johnson Replaced $913 Million In Lost Sales With $2.4 Billion In New Ones - But Kept Less Than Half
- Apollo in talks to acquire J&J’s orthopedics unit - Bloomberg
- Johnson & Johnson wins CE mark as new ACUVUE contact lens nears Europe launch
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
